William Blair analyst Myles Minter has maintained their bullish stance on AXSM stock, giving a Buy rating on September 17.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter’s rating is based on Axsome Therapeutics’ strong growth trajectory and promising financial outlook. The company is making significant strides with its drug Auvelity, which is generating substantial revenue in the major depressive disorder market and is expected to expand its application to Alzheimer’s disease agitation. This expansion, along with the diversification through other drugs like Sunosi, Symbravo, and AXS-12, positions Axsome as a leader in CNS therapeutics with a potential peak sales of $16.5 billion.
Minter also highlights Axsome’s robust financial health, with $303 million in cash as of the second quarter of 2025, which is projected to support the company until it reaches cash flow positivity. The company’s ability to potentially break even by the second half of 2026, while maintaining investment in R&D and SG&A, further strengthens its growth prospects. These factors collectively underpin Minter’s confidence in Axsome’s future performance, justifying the Buy rating.
In another report released on September 17, Piper Sandler also reiterated a Buy rating on the stock with a $148.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXSM in relation to earlier this year.